fbpx
Connect with us

News

Manus Neurodynamica announces appointment of non-executive director

The new key hires will support the development and launch of the company’s NeuroMotor pen

Published

on

Manus Neurodynamica announces appointment of non-executive director

Manus Neurodynamica announced the appointment of a new non-executive director and other key hires

The company has appointed Dr Guy Wood-Gush to the role of non-executive director onto the board of directors. Manus Neurodynamica has also appointed Dr Chris Papasavvas as the new senior data scientist and Angus Sturrock as technical operations and project manager.

The key hires to the board and senior management positions will help to support the commercial rollout of the company’s NeuroMotor Pen. It will ensure there is a breadth of knowledge, corporate collaboration, experience and sales expertise.

Manus Neurodynamica announces appointment of non-executive director

Manus develops and markets products and technologies for neuromotor assessment. Its principal product is a sensory pen designed for use in the diagnosis and monitoring of neuromotor impairments. The pen particularly focuses on patients with Parkinson’s disease and uses limb and hand motion to diagnose patients quickly and non-invasively.

It has applications across not just diagnosis but also screening, monitoring, rehabilitation and drug development for a number of different movement disorders.

Manus Neurodynamica announces appointment of non-executive director

Manus Neurodynamica

Dr Wood-Gush has a clinical background in ophthalmology and neurosurgery with over 20 years of commercial board expertise. He previously founded Deontics Ltd, an AI clinical decision support technology company and was chairman of Cambridge Cognition, a computerised cognitive testing software company. He was also the CEO of Cancer Research Ventures Ltd, which commercialised IP derived from research funded by the Cancer Research Campaign from 2001 to 2002.

He also worked in healthcare investment banking as a stock analyst at Barclays de Zoete Wedd and as a director of M&A at JP Morgan.

Angus Sturrock joins Manus as its new technical operations and project manager. He has 35 years of postgraduate experience in software development, test management, software quality, operations, people and project management. During his career, he has introduced multiple systems and devices to the market including blood glucose meters that have improved the lives of people with diabetes.

Dr Chris Papasavvas has joined Manus as a senior data scientist. He received his PhD from Newcastle University, focusing on neuroscientific research, and he gained post-doctoral research experience at Newcastle, Sussex and Yale. His research interests include neuroscience and computational neurology. His role will involve the collection and analysis of data from the NeuroMotor PenTM, in order to maximise the potential of the device in clinical practice.

Manus Neuromotor pen

Dr Guy Wood-Gush, non-executive director of Manus, said: “As a former clinician, the NeuroMotor Pen excites me as a product that could potentially change the lives of patients with neuromotor impairments. I’m looking forward to working with the Manus Board and the wider team as we look to build on the significant achievements of the Company to date.”

Dr Rutger Zietsma, CEO of Manus, commented: “I am delighted to welcome Guy, Angus and Chris to Manus. They are joining the Company at a pivotal stage, as we look to continue the commercial roll-out of our NeuroMotor Pen and conduct further research into its additional clinical uses.

“Guy’s significant experience at Board level and investment banking within the healthcare space, as well as his knowledge from his medical career, will be invaluable to us in progressing the Company’s vision.

Dr Rutger added: “Angus and Chris also bring strong skillsets to our already talented team; Angus’ proven track record in bringing medical devices to market, and Chris’ neuroscience expertise will be critical to Manus and the NeuroMotor Pen going forward.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories